Evaluation of the performance of the EIAgen HCV test for detection of hepatitis C virus infection

The EIAgen HCV test (Adaltis Inc., Montreal, Canada) is an enzyme immunoassay (EIA) for the detection of anti-hepatitis C virus (HCV) antibodies. This study compared the performance of this test side-by-side with the current Ortho HCV 3.0 Anti-HCV assay (Ortho-Clinical Diagnostics Inc., Johnson &...

Full description

Saved in:
Bibliographic Details
Published in:Journal of virological methods 2009-12, Vol.162 (1), p.203-207
Main Authors: Rao, Hui-Ying, Ren, Fu-Rong, Guan, Wen-Li, Houde, Michel, Du, Shao-Cai, Liu, Chang-Li, Gong, Xiao-Yan, Wei, Lai
Format: Article
Language:English
Subjects:
Anti-HCV
Biological and medical sciences
False Positive Reactions
Female
Fundamental and applied biological sciences. Psychology
Hepacivirus - immunology
Hepatitis C
Hepatitis C - diagnosis
Hepatitis C - immunology
Hepatitis C - virology
Hepatitis C Antibodies - blood
Hepatitis C virus
Humans
Immunoenzyme Techniques - methods
Microbiology
Performance evaluation
Predictive Value of Tests
Pregnancy
Reagent Kits, Diagnostic
Sensitivity
Sensitivity and Specificity
Specificity
Techniques used in virology
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The EIAgen HCV test (Adaltis Inc., Montreal, Canada) is an enzyme immunoassay (EIA) for the detection of anti-hepatitis C virus (HCV) antibodies. This study compared the performance of this test side-by-side with the current Ortho HCV 3.0 Anti-HCV assay (Ortho-Clinical Diagnostics Inc., Johnson & Johnson Company, Raritan, NY, USA). Among 2559 specimens examined, 178 were true positives, 2376 were true negatives and 5 were indeterminate. The sensitivity of the EIAgen HCV test was 100%, versus 98.3% for the Ortho HCV test, while their respective specificities were 98.1% and 98.2%. The EIAgen HCV test gave a positive predictive value of 79.8% and a negative predictive value of 100%. Overall, the concordance of this test with the Ortho HCV test was 98.2%. Specimens from potentially interfering substances, such as sera from pregnant women, sera from patients with acute non-C hepatitis, autoimmune diseases, lipidemia, or from patients undergoing hemolysis, showed no interference with either EIA. An EIAgen HCV test signal-to-cut-off ratio of >5.9 would be highly predictive of a true-positive finding in these specimens. The EIAgen HCV test is well suited for screening blood and blood products in antibodies to HCV.
ISSN:0166-0934
1879-0984
DOI:10.1016/j.jviromet.2009.08.008